Hoss Andrew G, Labadorf Adam, Beach Thomas G, Latourelle Jeanne C, Myers Richard H
Department of Neurology, Boston University School of MedicineBoston, MA, USA; Graduate Program in Genetics and Genomics, Boston University School of MedicineBoston, MA, USA.
Department of Neurology, Boston University School of MedicineBoston, MA, USA; Bioinformatics Program, Boston UniversityBoston, MA, USA.
Front Aging Neurosci. 2016 Mar 1;8:36. doi: 10.3389/fnagi.2016.00036. eCollection 2016.
The goal of this study was to compare the microRNA (miRNA) profile of Parkinson's disease (PD) frontal cortex with normal control brain, allowing for the identification of PD specific signatures as well as study the disease-related phenotypes of onset age and dementia.
Small RNA sequence analysis was performed from prefrontal cortex for 29 PD samples and 33 control samples. After sample QC, normalization and batch correction, linear regression was employed to identify miRNAs altered in PD, and a PD classifier was developed using weighted voting class prediction. The relationship of miRNA levels to onset age and PD with dementia (PDD) was also characterized in case-only analyses.
One twenty five miRNAs were differentially expressed in PD at a genome-wide level of significance (FDR q < 0.05). A set of 29 miRNAs classified PD from non-diseased brain (93.9% specificity, 96.6% sensitivity). The majority of differentially expressed miRNAs (105/125) showed an ordinal relationship from control, to PD without dementia (PDN), to PDD. Among PD brains, 36 miRNAs classified PDD from PDN (sensitivity = 81.2%, specificity = 88.9%). Among differentially expressed miRNAs, miR-10b-5p had a positive association with onset age (q = 4.7e-2).
Based on cortical miRNA levels, PD brains were accurately classified from non-diseased brains. Additionally, the PDD miRNA profile exhibited a more severe pattern of alteration among those differentially expressed in PD. To evaluate the clinical utility of miRNAs as potential clinical biomarkers, further characterization and testing of brain-related miRNA alterations in peripheral biofluids is warranted.
本研究的目的是比较帕金森病(PD)额叶皮质与正常对照脑的微小RNA(miRNA)谱,以确定PD特异性特征,并研究发病年龄和痴呆等疾病相关表型。
对29例PD样本和33例对照样本的前额叶皮质进行小RNA序列分析。在样本质量控制、标准化和批次校正后,采用线性回归来识别PD中改变的miRNA,并使用加权投票类预测开发了一个PD分类器。在仅病例分析中也对miRNA水平与发病年龄和帕金森病合并痴呆(PDD)的关系进行了表征。
在全基因组水平上有125个miRNA在PD中差异表达(FDR q<0.05)。一组29个miRNA可将PD与非患病脑区分开来(特异性为93.9%,敏感性为96.6%)。大多数差异表达的miRNA(105/125)呈现出从对照到无痴呆的PD(PDN)再到PDD的有序关系。在PD脑中,36个miRNA可将PDD与PDN区分开来(敏感性=81.2%,特异性=88.9%)。在差异表达的miRNA中,miR-10b-5p与发病年龄呈正相关(q=4.7e-2)。
基于皮质miRNA水平,可准确地将PD脑与非患病脑区分开来。此外,PDD的miRNA谱在PD中差异表达的那些miRNA中表现出更严重的改变模式。为了评估miRNA作为潜在临床生物标志物的临床实用性,有必要进一步表征和测试外周生物流体中与脑相关的miRNA改变。